Jim Xiang

List of Publications by Year
in descending order

166 papers	4,875 citations	94433 37 h-index	133252 59 g-index
166 all docs	166 docs citations	166 times ranked	5991 citing authors

#	Article	IF	Citations
1	The Energy Sensor AMPKÎ±1 Is Critical in Rapamycin-Inhibition of mTORC1-S6K-Induced T-cell Memory. International Journal of Molecular Sciences, 2022, 23, 37.	4.1	7
2	Prosurvival IL-7â€“Stimulated Weak Strength of mTORC1-S6K Controls T Cell Memory via Transcriptional FOXO1â€“TCF1â€“Id3 and Metabolic AMPKÎ±1â€“ULK1â€“ATG7 Pathways. Journal of Immunology, 2022, 208, 155-168.	0.8	7
3	Activation of Focal Adhesion Kinase Restores Simulated Microgravity-Induced Inhibition of Osteoblast Differentiation via Wnt/Î²-Catenin Pathway. International Journal of Molecular Sciences, 2022, 23, 5593.	4.1	8
4	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. Cellular and Molecular Immunology, 2021, 18, 2632-2647.	10.5	17
5	Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 9123.	4.1	91
6	Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 2793.	4.1	89
7	TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasisÂ. Cellular and Molecular Immunology, 2019, 16, 820-832.	10.5	37
8	Simulated microgravity inhibits cell focal adhesions leading to reduced melanoma cell proliferation and metastasis via FAK/RhoA-regulated mTORC1 and AMPK pathways. Scientific Reports, 2018, 8, 3769.	3.3	59
9	Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice. Vaccine, 2018, 36, 1414-1422.	3.8	19
10	An In Vitro Experimental Study of the Pulse Delivery Method in Irreversible Electroporation. Journal of Engineering and Science in Medical Diagnostics and Therapy, 2018, 1, .	0.5	4
11	Novel EXO-T vaccine using polyclonal CD4⁺ T cells armed with HER2-specific exosomes for HER2-positive breast cancer. OncoTargets and Therapy, 2018, Volume 11, 7089-7093.	2.0	27
12	A Critical Role of FAK/Rhoa Signaling in Simulated Microgravity-Altered Cell Apoptosis, Proliferation and Metastasis. Journal of Cell Signaling, 2018, 03, .	0.3	1
13	Mannose-6-phosphate receptor: a novel regulator of T cell immunity. Cellular and Molecular Immunology, 2018, 15, 986-988.	10.5	16
14	Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-Îº B and ERK1/2 Pathways. International Journal of Molecular Sciences, 2018, 19, 1994.	4.1	37
15	Multiple effects of CD40–CD40L axis in immunity against infection and cancer. ImmunoTargets and Therapy, 2018, Volume 7, 55-61.	5.8	50
16	Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cellular and Molecular Immunology, 2017, 14, 529-545.	10.5	30
17	CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection. Biochemical and Biophysical Research Communications, 2017, 484, 662-667.	2.1	6
18	mTORC1 regulates mannose-6-phosphate receptor transport and T-cell vulnerability to regulatory T cells by controlling kinesin KIF13A. Cell Discovery, 2017, 3, 17011.	6.7	17

#	Article	IF	Citations
19	CD8⁺ memory T-cell inflation renders compromised CD4⁺ T-cell-dependent CD8⁺ T-cell immunity via naïve T-cell anergy. ImmunoTargets and Therapy, 2017, Volume 6, 39-49.	5.8	0
20	The Tat Protein Enhances CTL Responses and Therapeutic Immunity of Gag-Specific Exosome-Targeted T Cell-Based Gag/Tat-Texo Vaccine in Transgenic HLA-A2 Mice. World Journal of Vaccines, 2017, 07, 11-25.	0.8	0
21	Simulated Microgravity Promotes Cell Apoptosis Through Suppressing Uev1A/TICAM/TRAF/NFâ€ºBâ€Regulated Antiâ€Apoptosis and p53/PCNAâ€•and ATM/ATRâ€Chk1/2â€Controlled DNAâ€Damage Response Pathways. Journal of Cellular Biochemistry, 2016, 117, 2138-2148.	2.6	32
22	Novel T-cell-based vaccines via arming polyclonal CD4⁺ T cells with antigen-specific exosomes. Immunotherapy, 2016, 8, 1265-1269.	2.0	4
23	IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. Cell and Bioscience, 2016, 6, 30.	4.8	32
24	Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Ligand Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation. Tumori, 2015, 101, 637-643.	1.1	5
25	Potent immunotherapy against wellâ€established thymoma using adoptively transferred transgene <i>ILâ€6</i>â€engineered dendritic cellâ€stimulated CD8⁺ Tâ€cells with prolonged survival and enhanced cytotoxicity. Journal of Gene Medicine, 2015, 17, 153-160.	2.8	6
26	Differential expression of mannose-6-phosphate receptor regulates T cell contraction. Journal of Leukocyte Biology, 2015, 98, 313-318.	3.3	22
27	HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer, 2015, 22, 101-116.	2.9	149
28	Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44+CD62Lhigh IL-7R+ CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cellular and Molecular Immunology, 2015, 12, 456-465.	10.5	16
29	Innate and Adoptive Immune Cells Contribute to Natural Resistance to Systemic Metastasis of B16 Melanoma. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 72-78.	1.0	5
30	Transgene IL-6 Enhances DC-Stimulated CTL Responses by Counteracting CD4+25+Foxp3+ Regulatory T Cell Suppression via IL-6-Induced Foxp3 Downregulation. International Journal of Molecular Sciences, 2014, 15, 5508-5521.	4.1	8
31	HIV-1 Gag-specific exosome-targeted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice. Trials in Vaccinology, 2014, 3, 19-25.	1.2	10
32	Natural CD8+25+ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma. Biochemical and Biophysical Research Communications, 2013, 438, 152-155.	2.1	71
33	Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice. Breast Cancer Research and Treatment, 2013, 140, 273-284.	2.5	37
34	Differential requirements of <scp>CD</scp>4⁺<scp>T</scp>â€cell signals for effector cytotoxic Tâ€lymphocyte (<scp>CTL</scp>) priming and functional memory <scp>CTL</scp> development at higher <scp>CD</scp>8⁺<scp>T</scp>â€cell precursor frequency. Immunology, 2013, 138, 298-306.	4.4	10
35	A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Cellular and Molecular Immunology, 2013, 10, 72-77.	10.5	29
36	Enhanced therapeutic efficacy of adenovirus-mediated interleukin-24 gene therapy combined with ionizing radiotherapy for nasopharyngeal carcinoma. Oncology Reports, 2013, 30, 1165-1174.	2.6	5

#	Article	IF	Citations
37	Th Cells Promote CTL Survival and Memory via Acquired pMHC-I and Endogenous IL-2 and CD40L Signaling and by Modulating Apoptosis-Controlling Pathways. PLoS ONE, 2013, 8, e64787.	2.5	13
38	A new dynamic model of three cell interactions for CTL responses. OncoImmunology, 2012, 1, 1430-1432.	4.6	4
39	Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Vaccine, 2012, 30, 3519-3525.	3.8	25
40	Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. Journal of Leukocyte Biology, 2012, 92, 289-300.	3.3	27
41	CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene. Molecular Immunology, 2012, 51, 143-149.	2.2	17
42	CD154 and IL-2 Signaling of CD4+ T Cells Play a Critical Role in Multiple Phases of CD8+ CTL Responses Following Adenovirus Vaccination. PLoS ONE, 2012, 7, e47004.	2.5	12
43	Synergistic Tumor Suppression by Adenovirus-Mediated Inhibitor of Growth 4 and Interleukin-24 Gene Cotransfer in Hepatocarcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 681-695.	1.0	22
44	GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses. Vaccine, 2011, 29, 3538-3547.	3.8	39
45	CD4+ T cell-released exosomes inhibit CD8+ cytotoxic T-lymphocyte responses and antitumor immunity. Cellular and Molecular Immunology, 2011, 8, 23-30.	10.5	97
46	Mechanisms of cellular communication through intercellular protein transfer. Journal of Cellular and Molecular Medicine, 2011, 15, 1458-1473.	3.6	128
47	A Distinct Role of CD4+ Th17- and Th17-Stimulated CD8+ CTL in the Pathogenesis of Type 1 Diabetes and Experimental Autoimmune Encephalomyelitis. Journal of Clinical Immunology, 2011, 31, 811-826.	3.8	30
48	Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunology, Immunotherapy, 2011, 60, 1473-1484.	4.2	81
49	Regulators of Tâ€cell memory generation: TCR signals versus CD4⁺ help?. Immunology and Cell Biology, 2011, 89, 578-580.	2.3	10
50	Membraneâ€bound HSP70â€engineered myeloma cellâ€derived exosomes stimulate more efficient CD8⁺ CTLâ€and NKâ€mediated antitumour immunity than exosomes released from heatâ€shocked tumour cells expressing cytoplasmic HSP70. Journal of Cellular and Molecular Medicine, 2010, 14, 2655-2666.	3.6	129
51	Tumor-derived HLA-G1 acquisition by monocytes through trogocytosis: possible functional consequences. Cellular and Molecular Life Sciences, 2010, 67, 4107-4108.	5.4	5
52	LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R. Molecular Immunology, 2010, 47, 2411-2421.	2.2	9
53	Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. Journal of Leukocyte Biology, 2010, 88, 393-403.	3.3	20
54	Dendritic Cells Recruit T Cell Exosomes via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity. Journal of Immunology, 2010, 185, 5268-5278.	0.8	106

#	Article	IF	Citations
55	Tumor Necrosis Factor Gene-Engineered J558 Tumor Cellâ€"Released Exosomes Stimulate Tumor Antigen P1A-Specific CD8⁺CTL Responses and Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 21-28.	1.0	26
56	Tumor-Suppressive Effect of Adenovirus-Mediated Inhibitor of Growth 4 Gene Transfer in Breast Carcinoma Cells <i>In Vitro</i> and <i>In Vivo</i>. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 427-437.	1.0	21
57	TheIn VitroandIn VivoAntitumor Activity of Adenovirus-Mediated Interleukin-24 Expression for Laryngocarcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 29-38.	1.0	12
58	Recombinant Human Interleukin-24 Suppresses Gastric Carcinoma Cell Growth<i>In Vitro</i>and<i>In Vivo</i>. Cancer Investigation, 2010, 28, 85-93.	1.3	23
59	Adenovirus-Mediated ING4 Expression Suppresses Pancreatic Carcinoma Cell Growth via Induction of Cell-Cycle Alteration, Apoptosis, and Inhibition of Tumor Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 261-269.	1.0	35
60	CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses. Journal of Immunology, 2009, 182, 193-206.	0.8	53
61	Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity via Membrane-Bound Transforming Growth Factor-Î²1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses. Cancer Research, 2009, 69, 7756-7766.	0.9	50
62	CD40 ligation converts TGF-Î²-secreting tolerogenic CD4âˆ'8âˆ' dendritic cells into IL-12-secreting immunogenic ones. Biochemical and Biophysical Research Communications, 2009, 379, 954-958.	2.1	10
63	Defect of CD8+ Memory T Cells Developed in Absence of IL-12 Priming for Secondary Expansion. Cellular and Molecular Immunology, 2008, 5, 147-152.	10.5	11
64	Intercellular Trogocytosis Plays an Important Role in Modulation of Immune Responses. Cellular and Molecular Immunology, 2008, 5, 261-269.	10.5	102
65	Acquired pMHC I Complexes Greatly Enhance CD4+ Th Cell's Stimulatory Effect on CD8+ T Cell-Mediated Diabetes in Transgenic RIP-mOVA Mice. Cellular and Molecular Immunology, 2008, 5, 407-415.	10.5	10
66	Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Letters, 2008, 271, 105-116.	7.2	62
67	T cell precursor frequency differentially affects CTL responses under different immune conditions. Biochemical and Biophysical Research Communications, 2008, 367, 427-434.	2.1	6
68	Antigen Specificity Acquisition of Adoptive CD4+ Regulatory T Cells via Acquired Peptide-MHC Class I Complexes. Journal of Immunology, 2008, 181, 2428-2437.	0.8	17
69	Active CD4⁺helper T cells directly stimulate CD8⁺cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet Î²-cell ovalbumin antigen leading to diabetes. Autoimmunity, 2008, 41, 501-511.	2.6	9
70	Disrupted RabGAP Function of the p85 Subunit of Phosphatidylinositol 3-Kinase Results in Cell Transformation. Journal of Biological Chemistry, 2008, 283, 15861-15868.	3.4	37
71	Recombinant Human IL-24 Suppresses Lung Carcinoma Cell Growth via Induction of Cell Apoptosis and Inhibition of Tumor Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 310-320.	1.0	26
72	TLR ligands efficiently convert tolerogenic CD4â€•8â€•DC into immunogenic ones stimulating longâ€•lasting antitumor immune response. FASEB Journal, 2008, 22, 1068.18.	0.5	0

#	Article	IF	Citations
73	Novel Exosome-Targeted CD4+ T Cell Vaccine Counteracting CD4+25+ Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory CD8+ CTL Responses. Journal of Immunology, 2007, 179, 2731-2740.	0.8	51
74	Adenovirus-Mediated Il-24 Expression Suppresses Hepatocellular Carcinoma Growth via Induction of Cell Apoptosis and Cycling Arrest and Reduction of Angiogenesis. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 56-63.	1.0	15
75	IL-10 Has A Distinct Immunoregulatory Effect on Naive and Active T Cell Subsets. Journal of Interferon and Cytokine Research, 2007, 27, 1031-1038.	1.2	36
76	Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. Journal of Leukocyte Biology, 2007, 82, 829-838.	3.3	51
77	Bidirectional membrane molecule transfer between dendritic and T cells. Biochemical and Biophysical Research Communications, 2007, 359, 202-208.	2.1	37
78	Alpha tumor necrosis factor contributes to CD8+ T cell survival in the transition phase. Biochemical and Biophysical Research Communications, 2007, 360, 702-707.	2.1	6
79	CD4+ T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL. Biochemical and Biophysical Research Communications, 2007, 362, 822-828.	2.1	24
80	Review: Cancer Immunotherapy by Exosome-Based Vaccines. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 692-703.	1.0	54
81	CD4+Th1 cells promote CD8+Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology, 2007, 120, 148-159.	4.4	77
82	Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology, 2007, 120, 90-102.	4.4	200
83	Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cellular and Molecular Immunology, 2007, 4, 105-11.	10.5	57
84	Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cellular and Molecular Immunology, 2007, 4, 277-85.	10.5	18
85	Intradermal Vaccination of Dendritic Cellâ€“Derived Exosomes Is Superior to a Subcutaneous One in the Induction of Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 146-154.	1.0	20
86	CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation. International Immunology, 2006, 18, 887-895.	4.0	6
87	Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Research, 2006, 16, 241-259.	12.0	35
88	CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. Journal of Leukocyte Biology, 2006, 80, 1354-1363.	3.3	27
89	In Vitro Activation of CD8 Interphotoreceptor Retinoid-Binding Protein-Specific T Cells Requires not only Antigenic Stimulation but also Exogenous Growth Factors. Journal of Immunology, 2006, 176, 5006-5014.	0.8	19
90	Conversion of Tolerogenic CD4Â¯8Â¯ Dendritic Cells to Immunogenic Ones Inducing Efficient Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 74-80.	1.0	3

#	Article	IF	Citations
91	Oncolytic Adenovirus-Mediated E1A Gene Therapy Induces Tumor-Cell Apoptosis and Reduces Tumor Angiogenesis Leading to Inhibition of Hepatocellular Carcinoma Growth in Animal Model. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 225-234.	1.0	14
92	CD8+ Cytotoxic T-APC Stimulate Central Memory CD8+ T Cell Responses via Acquired Peptide-MHC Class I Complexes and CD80 Costimulation, and IL-2 Secretion. Journal of Immunology, 2006, 177, 2976-2984.	0.8	39
93	Human Dendritic Cells Engineered to Express Alpha Tumor Necrosis Factor Maintain Cellular Maturation and T-Cell Stimulation Capacity. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 613-622.	1.0	12
94	Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cellular and Molecular Immunology, 2006, 3, 205-11.	10.5	91
95	CD4â^’8â^’ Dendritic Cells Prime CD4+ T Regulatory 1 Cells to Suppress Antitumor Immunity. Journal of Immunology, 2005, 175, 2931-2937.	0.8	61
96	Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Therapy, 2005, 12, 122-132.	4.6	25
97	Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. Journal of Gene Medicine, 2005, 7, 506-517.	2.8	24
98	Fusion Hybrid of Dendritic Cells and Engineered Tumor Cells Expressing Interleukin-12 Induces Type 1 Immune Responses against Tumor. Tumori, 2005, 91, 531-538.	1.1	14
99	Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer. Current Gene Therapy, 2005, 5, 237-247.	2.0	27
100	CD8Î±+, but Not CD8Î±â^’, Dendritic Cells Tolerize Th2 Responses via Contact-Dependent and -Independent Mechanisms, and Reverse Airway Hyperresponsiveness, Th2, and Eosinophil Responses in a Mouse Model of Asthma. Journal of Immunology, 2005, 175, 1516-1522.	0.8	43
101	Dendritic Cell/Myeloma Hybrid Vaccine. , 2005, 113, 225-234.		5
102	Molecular and Immunophenotypical Characterization of Progressive and Regressive Leukemia Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 290-299.	1.0	2
103	Vaccine of Engineered Tumor Cells Secreting Stromal Cellâ€"Derived Factor-1 Induces T-Cell Dependent Antitumor Responses. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 401-409.	1.0	9
104	Significant Tumor Regression Induced by Microencapsulation of Recombinant Tumor Cells Secreting Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 260-266.	1.0	8
105	A New Dynamic Model of CD8+ T Effector Cell Responses via CD4+ T Helper-Antigen-Presenting Cells. Journal of Immunology, 2005, 174, 7497-7505.	0.8	134
106	Tumor-Infiltrating Dendritic Cell Subsets of Progressive or Regressive Tumors Induce Suppressive or Protective Immune Responses. Cancer Research, 2005, 65, 4955-4962.	0.9	30
107	Engineered Fusion Hybrid Vaccine of IL-18 Gene-Modified Tumor Cells and Dendritic Cells Induces Enhanced Antitumor Immunity. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 322-330.	1.0	32
108	Synergistic effect of lymphotactin and interferon ?-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. International Journal of Cancer, 2004, 109, 817-825.	5.1	30

#	Article	IF	Citations
109	Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. Journal of Gene Medicine, 2004, 6, 857-868.	2.8	16
110	Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology, 2004, 26, 300-6.	0.1	22
111	Genetic Engineering of a Recombinant Fusion Protein Possessing an Antitumor Antibody Fragment and a TNF-Î± Moiety. , 2003, 215, 201-212.		1
112	Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Journal of Gene Medicine, 2003, 5, 668-680.	2.8	20
113	Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology, 2003, 108, 177-188.	4.4	54
114	CpG-Containing Oligodeoxynucleotide 1826 Converts the Weak Uveitogenic Rat Interphotoreceptor Retinoid-Binding Protein Peptide 1181â€"1191 into a Strong Uveitogen. Journal of Immunology, 2003, 171, 4780-4785.	0.8	18
115	Genetic Engineering of Dendritic Cells by Adenovirus-Mediated TNF-Î± Gene Transfer. , 2003, 215, 213-226.		1
116	Analysis of the Gene Expression Profiles of Immature versus Mature Bone Marrow-Derived Dendritic Cells Using DNA Arrays. Biochemical and Biophysical Research Communications, 2002, 290, 66-72.	2.1	56
117	Advances in Dendritic Cell-Based Vaccine of Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 601-619.	1.0	28
118	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 11-18.	1.0	12
119	DNA microarray analysis of the gene expression profiles of naÃ±Ì^ve versus activated tumor-specific T cells. Life Sciences, 2002, 71, 3005-3017.	4.3	31
120	Synergistic effect of adoptive T-cell therapy and intratumoral interferon Î³-inducible protein-10 transgene expression in treatment of established tumors. Cellular Immunology, 2002, 217, 12-22.	3.0	34
121	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. Cancer Gene Therapy, 2002, 9, 202-208.	4.6	44
122	Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Therapy, 2002, 9, 533-542.	4.6	40
123	Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Therapy, 2002, 9, 778-786.	4.6	33
124	Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leukemia Research, 2002, 26, 757-763.	0.8	59
125	Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Research, 2002, 62, 2043-51.	0.9	48
126	Neutrophils and B Cells Express XCR1 Receptor and Chemotactically Respond to Lymphotactin. Biochemical and Biophysical Research Communications, 2001, 281, 378-382.	2.1	56

#	Article	IF	Citations
127	Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. International Journal of Cancer, 2001, 93, 539-548.	5.1	151
128	DNA Array and Biological Characterization of the Impact of the Maturation Status of Mouse Dendritic Cells on Their Phenotype and Antitumor Vaccination Efficacy. Cellular Immunology, 2001, 214, 60-71.	3.0	39
129	Regression of engineered myeloma cells secreting interferon-Î³-inducing factor is mediated by both CD4+/CD8+ T and natural killer cells. Leukemia Research, 2001, 25, 909-915.	0.8	18
130	Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor. Journal of Immunology, 2001, 167, 57-65.	0.8	64
131	Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer Gene Therapy, 2000, 7, 37-44.	4.6	4
132	Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Therapy, 2000, 7, 1023-1033.	4.6	18
133	Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Therapy, 2000, 7, 1270-1278.	4.6	21
134	Regression of Engineered Tumor Cells Secreting Cytokines Is Related to a Shift in Host Cytokine Profile from Type 2 to Type 1. Journal of Interferon and Cytokine Research, 2000, 20, 349-354.	1.2	27
135	Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis. Protein Engineering, Design and Selection, 2000, 13, 339-344.	2.1	0
136	The Spectrum of Neuroendocrine Differentiation Among Gastrointestinal Carcinoids. Archives of Pathology and Laboratory Medicine, 2000, 124, 570-576.	2.5	53
137	Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Human Antibodies, 1999, 9, 23-36.	1.5	10
138	Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding. Protein Engineering, Design and Selection, 1999, 12, 417-421.	2.1	7
139	Substitution of Surface-Exposed Framework Residues Alters Secretion of Recombinant Fusion Protein Fv/Tumor Necrosis Factor in Escherichia coli. IUBMB Life, 1999, 48, 327-332.	3.4	3
140	Enzyme-linked immunosorbent assay-based selection and optimization of elution buffer for TAG72-affinity chromatography. Biomedical Applications, 1999, 731, 299-308.	1.7	5
141	Substitution of Surfaceâ€Exposed Framework Residues Alters Secretion of Recombinant Fusion Protein Fv/Tumor Necrosis Factor in Escherichia coli. IUBMB Life, 1999, 48, 327-332.	3.4	3
142	Adenovirus-mediated TNF-Î± Gene Transfer induces Significant Tumor Regression in Mice. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 49-57.	1.0	34
143	One Hundred Seventy-Fold Increase in Excretion of an FV Fragment-Tumor Necrosis Factor Alpha Fusion Protein (sFV/TNF-Î±) from <i>Escherichia coli</i> Caused by the Synergistic Effects of Glycine and Triton X-100. Applied and Environmental Microbiology, 1998, 64, 2869-2874.	3.1	71
144	Antitumor Vaccination with Gene-Transduced Tumor Cells Expressing a Fusion Protein RM4/IFN-Ï„. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 123-130.	1.0	1

#	Article	IF	Citations
145	Genetic engineering of a recombinant fusion possessing anti-tumor F(abâ€²)2 and tumor necrosis factor. Journal of Biotechnology, 1997, 53, 3-12.	3.8	21
146	Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-Ï„. Human Antibodies, 1996, 7, 21-26.	1.5	8
147	Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Human Antibodies, 1996, 7, 2-10.	1.5	7
148	Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library. , 1996, 24, 352-358.		9
149	Radioimmunoscintigraphy of Gastric Adenocarcinomas with 99mTc-Chimeric ccM4 Antibody. Cancer Biotherapy and Radiopharmaceuticals, 1996, 11, 125-131.	1.0	0
150	Mouse Myeloma Cell Line Secreting Bifunctional Fusion Protein RM4/IFN-Ï„ Elicits Antitumor CD8 MHC Class I-Restricted T Cells That Are Cytolytic<i>In Vitro</i>and Tumoricidal<i>In Vivo</i>. Journal of Interferon and Cytokine Research, 1996, 16, 771-776.	1.2	9
151	Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibodyâ€“TAG72 antigen interaction. Protein Engineering, Design and Selection, 1996, 9, 539-543.	2.1	8
152	A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells. Human Antibodies, 1995, 6, 161-166.	1.5	0
153	Expression of tumor-associated polymorphic epithelial mucin and carcinoembryonic antigen in gastrointestinal carcinoid tumors. Implications for immunodiagnosis and immunotherapy. Cancer, 1995, 75, 2836-2843.	4.1	11
154	Immunolocalization of hepatic metastases of human colonic cancer by chimeric anti-TAG72 antibody in scid mice. Journal of Surgical Oncology, 1995, 59, 3-9.	1.7	7
155	A genetically engineered single-chain FVTNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Molecular Immunology, 1995, 32, 873-881.	2.2	29
156	Framework Residues 71 and 93 of the Chimeric B72.3 Antibody are Major Determinants of the Conformation of Heavy-chain Hypervariable Loops. Journal of Molecular Biology, 1995, 253, 385-390.	4.2	33
157	Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Gastroenterology, 1995, 109, 1950-1957.	1.3	7
158	Cloning and Expression of Functional cDNA Genes of a Mouse/Human Chimeric Antibody rcM4. Tumori, 1994, 80, 473-479.	1.1	2
159	Singleâ€chain antibody variable regionâ€targeted interleukinâ€2 stimulates T cell killing of human colorectal carcinoma cells. Immunology and Cell Biology, 1994, 72, 275-285.	2.3	9
160	Differences in antigenâ€binding affinity caused by single amino acid substitution in the variable region of the heavy chain. Immunology and Cell Biology, 1993, 71, 239-247.	2.3	7
161	High-affinity chimeric anti-(colorectal carcinoma) antibody correlated to enhanced tumor targeting in biodistribution and imaging. Journal of Cancer Research and Clinical Oncology, 1993, 120, 57-62.	2.5	3
162	Recombinant Bifunctional Molecule FV/IFN-Î³ Possesses the Anti-Tumor FV as Well as the Gamma Interferon Activities. Cancer Biotherapy, 1993, 8, 327-337.	0.5	9

#	ARTICLE	IF	CITATIONS
163	The Tyrosine Residue at Position 97 in the V_HCDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen. Cancer Biotherapy, 1993, 8, 253-262.	0.5	1
164	High Binding Affinity Chimeric Anti-Colorectal Carcinoma Antibody Correlated to Enhanced Tumor Binding and Effector Function. Cancer Biotherapy, 1993, 8, 171-180.	0.5	2
165	Production and Characterization of a Tumor-Specific Monoclonal Antibody Act19 Recognizing an Epitope Distinctive from Sialosyl-Tn on the TAG72 Antigen. Tumori, 1993, 79, 58-65.	1.1	7
166	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. , 0, .		1